GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration

Luis Quintino1 • Martino Avallone1 • Emil Brännstrom1 • Patrick Kavanagh1 • Marcus Lockowandt1 • Patricia Garcia Jareño1 • Ludivine S Breger1 • Cecilia Lundberg1

Received: 12 February 2018 / Revised: 1 October 2018 / Accepted: 12 October 2018 / Published online: 7 December 2018 © The Author(s) 2018. This article is published with open access

Abstract
Glial cell-line derived neurotrophic factor (GDNF) is a promising therapeutic molecule to treat Parkinson’s disease. Despite an excellent profile in experimental settings, clinical trials testing GDNF have failed. One of the theories to explain these negative outcomes is that the clinical trials were done in late-stage patients that have advanced nigrostriatal degeneration and may therefore not respond to a neurotrophic factor therapy. Based on this idea, we tested if the stage of nigrostriatal degeneration is important for GDNF-based therapies. Lentiviral vectors expressing regulated GDNF were delivered to the striatum of rats to allow GDNF expression to be turned on either while the nigrostriatal system was degenerating or after the nigrostriatal system had been fully lesioned by 6-OHDA. In the group of animals where GDNF expression was on during degeneration, neurons were rescued and there was a reversal of motor deficits. Turning GDNF expression on after the nigrostriatal system was lesioned did not rescue neurons or reverse motor deficits. In fact, these animals were indistinguishable from the control groups. Our results suggest that GDNF can reverse motor deficits and nigrostriatal pathology despite an ongoing nigrostriatal degeneration, if there is still a sufficient number of remaining neurons to respond to therapy.

Introduction
Glial cell-line derived neurotrophic factor (GDNF) is a promising therapeutic agent to treat Parkinson’s disease (PD). Delivery of GDNF or GDNF family ligands (GFLs) to the striatum protects, regenerates, and improves the metabolism of substantia nigra pars compacta neurons (SNpc), a key neuronal population degenerating during PD pathogenesis [1–6], resulting in amelioration of motor deficits in PD models. The potent therapeutic effects of GFL resulted in the development of clinical trials to test if GDNF or GFL such as Neurturin can modify PD progression. Despite initial promise [7–10], large-scale clinical trials of GDNF and Neurturin have not been successful [5, 6, 11, 12] in rescuing the nigrostriatal system and improving motor deficits. Why did these clinical trials fail?

One theory postulates that the GDNF pathway is compromised in SNpc neurons of PD patients due to alpha-synuclein pathology [13] and for that reason, PD patients do not respond to GDNF treatment. Although this theory is supported by experimental data, a recent systematic study analyzing brains from PD patients, together with several animal models of PD, did not find any impairments in the GDNF pathway [14], suggesting that the deficits seen previously may be due to the specific experimental model used [13, 15]. Another theory proposes that drug delivery protocols were suboptimal, resulting in limited distribution of neurotrophic factors in the brain parenchyma that prevented the possibility of observing a therapeutic benefit [16]. Analysis of catheters and infusion protocols used in the GDNF trials, experimental studies testing GDNF delivery protocols in primates [17–19] as well as brains from patients that participated in the Neurturin clinical trial [16] seem to support this theory. The last theory proposes that the nigrostriatal degeneration in patients selected for clinical trials may have been too advanced for the patients to respond to GFL therapy [16]. This theory is supported by two sets of data. The first comes from the Neurturin trial, where stronger motor recovery was seen in patients with <5 years of disease [20]. The second...
comes from a study from Kordower et al. [21], analysis of brains from PD patients indicated that SNpc cells and dopaminergic terminals in the putamen seem to be lost within the first 4–7 years of diagnosis.

We set out to test if the therapeutic benefits of GDNF on SNpc neurons and motor behavior are dependent on the degree of nigrostriatal degeneration. We observed that if GDNF was given when the nigrostriatal system was fully degenerated there was no recovery. To rescue the nigrostriatal system and motor deficits, GDNF needed to be present in the striatum when there were still a significant number of impaired SNpc neurons to respond to therapy.

Results and discussion

Experimental design

To determine if the therapeutic effects of GDNF are dependent on the degree of nigrostriatal degeneration, lentiviral vectors expressing destabilizing domain (DD)-regulated yellow fluorescence protein (LV-YFP-DD) or DD-regulated GDNF (LV-GDNF-F-DD) [22–24] were delivered to the striatum of rats and the experiment was performed as shown in Fig. 1. DD regulation was achieved by making a fusion protein of a protein of interest with a DD, a mutated degradation-prone protein or peptide. Due to the presence of the DD, the full fusion protein is targeted for proteasomal degradation. The DD is designed so that proteasomal recognition could be blocked by a drug. The DD used in this study requires trimethoprim (TMP) to block proteasomal recognition [22–24].

The animals were lesioned with an intrastriatal 6-OHDA lesion protocol so that the vast majority of susceptible SNpc cells would die progressively within the first 4–5 weeks of lesion [25–27], providing a window of progressive degeneration to test the hypothesis that the benefits of GDNF on SNpc are dependent on the degree of nigrostriatal degeneration.

One subgroup of LV-GDNF-F-DD animals was used to test if GDNF could rescue the dopaminergic system from an ongoing degeneration (Rescue), modeling nigrostriatal pathology at time of PD diagnosis. As SNpc neurons need 2–3 weeks of continuous TMP treatment to respond to GDNF-F-DD [23] and the 6-OHDA degeneration occurs within 4–5 weeks, TMP treatment was started 1 week before 6-OHDA to allow SNpc neurons to respond to GDNF-F-DD induction when half of the SNpc neurons have died due to 6-OHDA but a significant number of impaired SNpc neurons remained to regenerate the nigrostriatal system.

Another subgroup of LV-GDNF-F-DD was used to test if GDNF could regenerate the nigrostriatal system after most of the SNpc neurons have died (Regeneration), modeling end-stage nigrostriatal pathology seen in advanced PD. TMP treatment was started 3 weeks after 6-OHDA lesion, therefore GDNF-F-DD activation of SNpc neurons reached maximum levels 5–6 weeks after lesion, when the vast majority of SNpc neurons have already died from 6-OHDA.

GDNF can rescue SNpc neurons and motor function

Immunohistochemistry for GDNF (Fig. 2a) showed expression in the Rescue and Regeneration groups and minimal staining for the OFF group. This is in line with previous observations and quantifications of GDNF-F-DD expression in vivo [22, 23].

Immunohistochemistry for tyrosine hydroxylase (TH) (Fig. 2a) indicated a severe striatal denervation in the YFP-DD, Regeneration, and OFF groups, which was ameliorated in the Rescue group. There was also a severe
reduction of SNpc TH-positive neurons in all groups. Similarly, quantification of TH neurons in SNpc (Fig. 2b) confirmed a higher number surviving TH neurons in the Rescue group when compared to the remaining groups. One-way analysis of variance (ANOVA; $F = 8.7, p = 0.0003$) and subsequent post hoc test showed a statistically significant difference in TH-positive neurons between Rescue and all other groups.
Immunohistochemistry for vesicular monoamine transporter 2 (VMAT2) (Fig. 2a, c) indicated striatal denervation and SNpc degeneration levels similar to TH. The Rescue group seemed to have the strongest striatal VMAT2 staining and the highest number of SNpc VMAT2 neurons. One-way ANOVA analysis of VMAT2 neurons indicated differences between groups ($F = 3.5$, $p = 0.02$) and post hoc analysis confirmed a statistically significant difference in VMAT2-positive neurons between Rescue and YFP-DD groups. There was a higher variability in the VMAT2 neuron numbers when compared with TH neuron numbers that may explain why we could only detect a difference between the Rescue and YFP-DD groups.

SNpc sections were also stained for phosphorylated ribosomal protein S6 (pRPS6). This protein is downstream of Akt and Erk signaling pathways. RPS6 is phosphorylated in SNpc neurons due to GDNF-mediated activation of signaling pathways and for that reason has been used as a marker for GDNF activity in SNpc cells [13, 22, 23]. Similarly, to TH and VMAT2, there were increased numbers of pRPS6 neurons in the Rescue group when compared with the remaining groups (Fig. 2a, d). One-way ANOVA revealed statistically significant differences between groups ($F = 8.2$, $p = 0.0006$) and post hoc analysis indicated a difference in pRPS6 neuron numbers between the Rescue and all remaining groups.

Interestingly, pRPS6 immunohistochemistry also showed surviving SNpc neurons with more intense pRPS6 staining and increased perikarya size in the injected hemispheres of Rescue and Regeneration groups. According to the literature, increased pRPS6 cell numbers, stronger staining [13, 22], and increased SNpc neuron perikarya size [28, 29] suggest that these neurons were responding to GDNF.

Fig. 3 GDNF-F-DD leads to partial recovery of motor impairment when there is an ongoing nigrostriatal degeneration. a Amphetamine-induced rotations measured 7, 14, and 19 weeks after 6-OHDA lesion ($n = 8–10$ per group). One-way ANOVA with Tukey multiple comparison tests performed on week 19. Repeated-measures ANOVA with Tukey multiple comparison tests performed on weeks 7, 14, and 19 was statistically significant in the Rescue group. *$p \leq 0.05$, **$p \leq 0.01$, ***$p \leq 0.0001$. b Correlation between numbers of TH neurons and amphetamine-induced rotations on week 19. c Correlation between numbers of VMAT2 neurons and amphetamine-induced rotations on week 19. d Correlation between numbers of pRPS6 neurons and amphetamine-induced rotations on week 19.
there was a therapeutic response of GDNF-F-DD in the Rescue group in contrast with the remaining groups.

Assessment of motor deficits was done by amphetamine-induced rotations (Fig. 3a). At 7 weeks after lesion, all groups exhibited a strong rotational bias, indicative of severe nigrostriatal degeneration. Interestingly, 14 and 19 weeks after lesion, the Rescue group showed a progressive decrease in the number of ipsilateral rotations, suggesting that a rescue of nigrostriatal degeneration was taking place. In contrast, the rotational bias levels were constantly high at all time points for Regeneration, YFP-DD, and OFF groups. Repeated-measures ANOVA showed that only the Rescue group showed a statistically significant reduction of amphetamine-induced rotational behavior ($F = 14.3, p = 0.001$) between weeks 7 and 19 after lesion. In addition, one-way ANOVA comparing the rotational bias of the different groups on week 19 indicated differences between groups ($F = 6.6, p = 0.002$). Subsequent post hoc analysis showed differences between the Rescue, YFP-DD, and OFF groups. The motor assessment suggested that there was therapeutic response of GDNF-F-DD in the Rescue group in contrast with the remaining groups.

Correlation analysis comparing the cell counts and rotational bias at week 19 after lesion showed a significant reverse correlation (Fig. 3b–d). When the individual values were sorted by experimental group, it became clear that the animals from the Rescue group clustered apart from the remaining groups, with negligible differences between Regeneration, OFF, and YFP-DD groups.

The behavior and histological data indicate that our results are not due to neuroprotection from GDNF-F-DD. We observed no protection of motor impairments at 7 weeks after lesion, nor did we observe a high number of surviving SNpc cells. These are two key aspects observed when viral vectors expressing GDNF are given in a neuroprotective paradigm (i.e. SNpc neurons respond to GDNF before the lesion): there is a higher number of surviving SNpc neurons and a significant protection of motor impairment already 7 weeks post lesion [30–36]. When we previously tested GDNF-F-DD for neuroprotection, and in contrast with the current study, we observed a significantly higher number of surviving SNpc neurons and a significant protection from motor impairments already 6 weeks after lesion.

The data suggest instead that the GDNF-F-DD therapeutic response was due to a rescue of impaired SNpc cells. Our study is in accordance with literature showing that GDNF can rescue an impaired nigrostriatal system. In studies where GDNF protein [29, 37–40] or viral vectors expressing GDNF [41–45] were given 4 weeks after 6-OHDA lesion, there was a milder lesion that resulted in 20–40% living SNpc neurons in control groups. We observed 10% surviving neurons in the YFP, Regeneration, and OFF groups. Thus, the GDNF groups in these previous studies are comparable to the Rescue group where there was still a critical number of surviving SNpc neurons that enabled rescue of the nigrostriatal system. Moreover, when GDNF was given 2 weeks after 6-OHDA, mimicking the situation in the Rescue group, the level of motor recovery and nigrostriatal pathology was similar [46] to what we have observed.

Our study is the first directly comparing the response of the nigrostriatal system to GDNF in two important conditions: during ongoing degeneration and/or in a fully degenerated nigrostriatal system. The results indicate that for GDNF to be effective, it needs to be given when sufficient SNpc neurons are still present. Below a certain threshold, the surviving neurons will respond to GDNF but their numbers will not allow a rescue of nigrostriatal pathology.

The regulated GDNF-F-DD we have developed makes it possible to design studies to fine-tune GFL therapies. For example, it will allow us to pinpoint where the threshold for GDNF-mediated recovery is, as well as allow us to determine for how long the GDNF-mediated recovery of the nigrostriatal system can be maintained.

Importantly, the current study supports the idea that the GDNF/GLF clinical trials need to target a cohort of PD patients that is as close as possible to the time of diagnosis in order for the GDNF/GLF therapy to be successful. In addition to selecting less advanced patients, the poor distribution of Neurturin in the putamen of patients in the CERE-120 trial also highlighted the need for better delivery protocols and vector technologies [16]. If predictive biomarkers for PD can be developed, it will be possible in the future do provide GFL therapies to patients where the nigrostriatal pathology is still at subclinical levels, thereby maximizing the recovery of the nigrostriatal system.

**Materials and methods**

**Viral vector production**

Plasmids, cell culture conditions, and viral vector production details have been described in detail elsewhere [22, 23]. The LV had the functional titers of $1 \times 10^9$ transducing units/ml.

**Animal experiments**

All animals were housed and handled according to European and Swedish laws. All procedures have been approved and performed according to the guidelines established by the Ethical Committee for Use of Laboratory Animals at Lund University under the permit M366-12. A total of 40 Female
Sprague Dawley rats, 10 per experimental group (Charles River, Sulzfeld, Germany), weighing 225–250 g were used for the experiments. 6-OHDA surgeries have been described in detail elsewhere [22]. Briefly, the 6-OHDA dosage was 2 × 10 µg of free-base 6-OHDA diluted in 3.5 µg/µl, delivered to the following coordinates with the tooth bar set at 0: (1) anteroposterior (AP) +0.5 mm, mediolateral (ML) −2.5 mm, dorsoventral (DV) −5 mm. (2) AP −0.5 mm, ML −4.2 mm, DV −5 mm. Viral vector surgeries have been described in detail elsewhere [22, 23]. Viral suspensions were delivered to three sets of coordinates: (1) AP +1.4 mm, ML −2.6 mm, DV −5/−4 mm. (2) AP +0.4 mm, ML −3.8 mm, DV −5/−4 mm. (3) AP −0.8 mm, ML −4.4 mm, DV −5/−4 mm. Tooth bar was set at 0 and a total of 6 µl of lentiviral vector suspension (1 µl/DV coordinate) was delivered at a rate of 0.4 µl/min. Perfusions were performed as described previously [22].

**TMP treatments**

TMP (TMP oral suspension 10 mg/ml; Meda AB, Solna, Sweden) was diluted in water to 0.2 mg/ml and given to the animals in their drinking water continuously throughout the experiment.

**Behavioral assessment**

Drug-induced rotations were performed using 2.5 mg/kg d-amphetamine sulfate over a period of 90 min as described previously [22].

**Histological analysis**

Standard immunohistochemistry procedures have been described in detail elsewhere [22, 23]. The brains were cut into six series containing 35 µm-thick sections. For each staining, one series was used per animal. The samples were rinsed three times in 0.1 M potassium phosphate buffer saline (KPBS) and incubated for 15 min in quenching solution (KPBS, 10% methanol and 3% H2O2). The samples were then rinsed three times in KPBS and incubated for 1 h in 5% serum solution (KPBS + 5% horse or goat serum + 0.25% Triton X). Samples were then incubated overnight with primary antibody diluted in 5% serum solution. On the next day, samples were washed two times in KPBS, incubated for 15 min in 5% serum solution, and incubated for 1 h with secondary antibodies diluted in 5% serum solution. The samples were subsequently washed for three times with KPBS, incubated 1 h with KPBS containing ABC complex and washed further three times with KPBS. The samples were incubated with KPBS containing 0.5 mg/ml 3,3-diaminobenzidine for 2 min. The reaction was then visualized by incubating the samples with 10 µl H2O2 solution (KPBS + 0.9% H2O2) for 2–4 min. The samples were washed three times in KPBS, mounted, and covered-slipped using DPX mounting medium. For the VMAT2 and pRPS6 staining, samples were incubated in Tris-EDTA Buffer (10 mM Tris base, 1 mM EDTA, and 0.05% Tween 20, pH 9) for 10 min at 80 °C before quenching. The following antibodies were used: rabbit anti pRPS6 (#2211, 1:2000, Cell Signaling Technology); goat anti-human GDNF (AF-212-NA, 1:1000, R&D Systems Europe); rabbit anti-TH (AB152, 1:1000, Merck); rabbit anti-VMAT2 (20042, 1:8000, Immunostar); biotinylated horse anti-mouse (BA2001, 1:200, Vector Labs, Peterborough, UK); biotinylated horse anti-goat (BA9500, 1:200, Vector Labs); and biotinylated goat anti-rabbit-biotin (BA1000, 1:200, Vector Labs).

**Quantification of cell numbers**

Quantification of SNpc cell numbers has been described in detail elsewhere [22, 23]. Briefly, three coronal sections were used to quantify TH, VMAT2, pRPS6 positive SNpc neurons: the coronal section containing medial lemniscus separating ventral tegmental area from SNpc (approximately −5 mm relative to bregma), adjacent cranial section, and adjacent caudal section. Data were presented as a percentage of neurons relative to the left intact side.

**Statistics**

Statistical analysis was performed using Graphpad Prism 7 (Graphed Software, La Jolla, CA). Figures show mean ± standard error of mean. When one-way ANOVA was performed, post hoc analysis was done using Tukey multiple comparison tests. When repeated-measures ANOVA was performed, post hoc analysis was done using Tukey multiple comparison tests.

**Acknowledgements** The authors thank Ulla Jarl, Michael Sparrenius, and Bengt Mattsson for expert technical assistance.

**Funding** The work was supported with funding from the Swedish Research Council (#2014-3258), the Swedish Brain Foundation, and Swedish Parkinson Foundation. The work was also supported with infrastructure, personnel, and funding from the BAGADILICO and MULTIPARK consortia at Lund University.

**Author contributions** LQ and CL conceived the study. LQ, MA, EB, PK, PGJ, and LSB performed experiments. LQ, MA, EB, PK, ML, and CL analyzed data. LQ prepared the figures and wrote the manuscript. CL secured funding.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

---

**Funding**

The work was supported with funding from the Swedish Research Council (#2014-3258), the Swedish Brain Foundation, and Swedish Parkinson Foundation. The work was also supported with infrastructure, personnel, and funding from the BAGADILICO and MULTIPARK consortia at Lund University.

**Author contributions**

LQ and CL conceived the study. LQ, MA, EB, PK, PGJ, and LSB performed experiments. LQ, MA, EB, PK, ML, and CL analyzed data. LQ prepared the figures and wrote the manuscript. CL secured funding.

**Compliance with ethical standards**

Conflict of interest The authors declare that they have no conflict of interest.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Blits B, Petry H. Perspective on the road toward gene therapy for Parkinson’s disease. Front Neuroanat. 2016;10:128.
2. Kirik D, Cederfjall E, Halliday G, Petersen A. Gene therapy for Parkinson’s disease: disease modification by GDNF family of ligands. Neurobiol Dis. 2017;97(Pt B):179–88.
3. Kordover JH, Bjorklund A. Trophic factor gene therapy for Parkinson’s disease. Mov Disord. 2013;28:96–109.
4. O’Connor DM, Boulis NM. Gene therapy for neurodegenerative diseases. Trends Mol Med. 2015;21:504–12.
5. Olanow CW, Bartus RT, Volpicelli-Daley LA, Bjorklund A. Trophic factors for Parkinson’s disease: to live or let die. Mov Disord. 2015;30:1715–24.
6. Tenenbaum L, Humbert-Claude M. Glial cell line-derived neurotrophic factor gene delivery in parkinson’s disease: a delicate balance between neuroprotection, trophic effects, and unwanted compensatory mechanisms. Front Neuroanat. 2017;11:29.
7. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, et al. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg. 2007;106:614–20.
8. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputaminal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol. 2005;57:298–302.
9. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med. 2005;11:703–4.
10. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 2005;102:216–22.
11. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputaminal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59:459–66.
12. Kordover JH. AAV2-Neurturin for Parkinson’s disease: what lessons have we learned? Methods Mol Biol. 2016;1382:485–90.
13. Decressac M, Kadhkhodaei B, Mattsson B, Laguna A, Perlmann T, Bjorklund A. alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med. 2012;4:163ra56.
14. Su X, Fischer DL, Li X, Bankiewicz K, Sortwell CE, Fedoroff HJ. Alpha-Synuclein mRNA is not increased in sporadic pd and alpha-synuclein accumulation does not block GDNF signaling in Parkinson’s disease and disease models. Mol Ther. 2017;25:2231–5.
15. Lo Bianco C, Deglon N, Pralong W, Aebischer P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson’s disease. Neurobiol Dis. 2004;17:283–9.
16. Bartus RT, Kordover JH, Johnson EM Jr., Brown L, Kruegel BR, Chu Y, et al. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with alpha-synucleinopathies. Neurobiol Dis. 2015;78:162–71.
17. Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z, et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol. 2006;202:497–505.
18. Patel NK, Gill SS. GDNF delivery for Parkinson’s disease. Acta Neurochir Suppl. 2007;97(2):135–54.
19. Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson’s disease and nonhuman primate brains. Mov Disord. 2011;26:27–36.
20. Marks WJ Jr., Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9:1164–72.
21. Kordover JH, Olanow CW, Dodia HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013;136(Pt 8):2419–31.
22. Quintino L, Manfre G, Wettergren EE, Namislo A, Isaksson C, Lundberg C. Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson’s disease. Mol Ther. 2013;21:2169–80.
23. Quintino L, Namislo A, Davidsson M, Breger LS, Kavanagh P, Avallone M, et al. Destabilizing Domains enable long-term and inert regulation of GDNF expression in the brain. Mol Ther Methods Clin Dev. 2018;11:29–39.
24. Tai K, Quintino L, Isaksson C, Gussing F, Lundberg C. Destabilizing domains mediate reversible transgene expression in the brain. PLoS ONE. 2012;7:e46269.
25. Bjorklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson’s disease. Neurobiol Dis. 1997;4:186–200.
26. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastratal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neurosciience. 1994;59:401–15.
27. Oiwa Y, Sanchez-Pernaute R, Harvey-White J, Bankiewicz KS. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease. J Neurosurg. 2003;98:136–44.
28. Gash DM, Zhang Z, Cass WA, Ovadia A, Simmerman L, Martin D, et al. Morphological and functional effects of intranigral administered GDNF in normal rhesus monkeys. J Comp Neurol. 1995;363:345–58.
29. Bowenkamp KE, Hoffman AF, Gerhardt GA, Henry MA, Biddle PT, Hoffer BJ, et al. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol. 1995;355:479–89.
30. Bensadoun JC, Deglon N, Tseng JL, Ridet JL, Zum AD, Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson’s disease using GDNF. Exp Neurol. 2000;164:15–24.
31. Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA. 1997;94:8818–23.
32. Choi-Lundberg DL, Lin Q, Schallert T, Crippens D, Davidson BL, Chang YN, et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol. 1998;154:261–75.
33. Dowd E, Monville C, Torres EM, Wong LF, Azzouz M, Mazarakis ND, et al. Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Eur J Neurosci. 2005;22:2587–95.
34. Georgievska B, Kirik D, Rosenblad C, Lundberg C, Bjorklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport. 2002;13:75–82.
35. Kirik D, Rosenblad C, Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci. 2000;12:3871–82.
36. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci. 2000;20:4686–700.
37. Aoi M, Date I, Tomita S, Ohmoto T. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res. 2000;36:319–25.
38. Aoi M, Date I, Tomita S, Ohmoto T. Single administration of GDNF into the striatum induced protection and repair of the nigrostriatal dopaminergic system in the intrastriatal 6-hydroxydopamine injection model of hemiparkinsonism. Restor Neurol Neurosci. 2000;17:31–8.
39. Rosenblad C, Martinez-Serrano A, Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson’s disease. Neuroscience. 1998;82:129–37.
40. Yue X, Hariri DJ, Caballero B, Zhang S, Bartlett MJ, Kaut O, et al. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson’s disease. Neuroscience. 2014;258:385–400.
41. McGrath J, Lintz E, Hoffer BJ, Gerhardt GA, Quintero EM, Granholm AC. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transplant. 2002;11:215–27.
42. Yang X, Mertens B, Lehtonen E, Vercammen L, Bockstael O, Ch tarto A, et al. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson’s disease rat model. J Gene Med. 2009;11:899–912.
43. Brizard M, Carcenac C, Bemelmans AP, Feuerstein C, Mallet J, Savasta M. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson’s disease. Neurobiol Dis. 2006;21:90–101.
44. Zheng JS, Tang LL, Zheng SS, Zhan RY, Zhou YQ, Goudreau J, et al. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson’s disease. Brain Res Mol Brain Res. 2005;134:155–61.
45. Lapchak PA, Araujo DM, Hilt DC, Sheng J, Jiao S. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson’s disease. Brain Res. 1997;777:153–60.
46. Kirik D, Georgievska B, Rosenblad C, Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson’s disease. Eur J Neurosci. 2001;13:1589–99.